Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease

被引：145

作者：

Kappel, Ben A. ^{[1
]}

Lehrke, Michael ^{[1
]}

Schutt, Katharina ^{[1
]}

Artati, Anna ^{[2
]}

Adamski, Jerzy ^{[2
,3
,4
]}

Lebherz, Corinna ^{[1
]}

Marx, Nikolaus ^{[1
]}

机构：

[1] Rhein Westfal TH Aachen, Univ Hosp Aachen, Dept Internal Med 1, Pauwelsstr 30, D-52074 Aachen, Germany

[2] German Res Ctr Environm Hlth, Helmholtz Zentrum Muchen, Genome Anal Ctr, Inst Expt Genet, Neuherberg, Germany

[3] Tech Univ Munich, Life & Food Sci Ctr Weihenstephan, Inst Expt Genet, Freising Weihenstephan, Germany

[4] German Ctr Diabet Res, Neuherberg, Germany

来源：

CIRCULATION | 2017年 / 136卷 / 10期

关键词：

branched-chain amino acids; cardiovascular disease; empagliflozin; ketone bodies; metabolomics; SGTL2; inhibitors; type 2 diabetes mellitus; OUTCOMES;

D O I：

10.1161/CIRCULATIONAHA.117.029166

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：969 / 972

页数：4

共 50 条

[21] Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy [J].

Lingvay, Ildiko ;

Greenberg, Michelle ;

Gallo, Silvina ;

Shi, Harry ;

Liu, Jie ;

Gantz, Ira .

DIABETES OBESITY & METABOLISM, 2021, 23 (07) :1640-1651

[22] The cost of cardiovascular-disease-related death in patients with type 2 diabetes mellitus [J].

Shetty, Sharash ;

Stafkey-Mailey, Dana ;

Yue, Binglin ;

Coutinho, Anna D. ;

Wang, Weijia ;

Del Parigi, Angelo ;

Sander, Stephen D. ;

Coleman, Craig, I .

CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (06) :1081-1087

[23] Effect of Add-On Therapy of Dapagliflozin and Empagliflozin on Adipokines in Type 2 Diabetes Mellitus [J].

Shaheer, Abid ;

Kumar, Ashok ;

Menon, Palat ;

Jallo, Mahir ;

Basha, Shaikh .

JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2021, 11 (3-4) :83-90

[24] Options for empagliflozin in combination therapy in type 2 diabetes mellitus [J].

Hershon, Kenneth S. .

INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2016, 9 :155-172

[25] Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus [J].

John E. Anderson ;

Eugene E. Wright ;

Charles F. Shaefer .

Diabetes Therapy, 2017, 8 :33-53

[26] Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus [J].

Lai, Lee-Lee ;

Vethakkan, Shireene Ratna ;

Nik Mustapha, Nik Raihan ;

Mahadeva, Sanjiv ;

Chan, Wah-Kheong .

DIGESTIVE DISEASES AND SCIENCES, 2020, 65 (02) :623-631

[27] Epidemiological Evidence of Type 2 Diabetes Mellitus, Metabolic Syndrome, and Cardiovascular Disease in Japan [J].

Saito, Isao .

CIRCULATION JOURNAL, 2012, 76 (05) :1066-1073

[28] The Effect of Empagliflozin on Liver Fat in Type 2 Diabetes Mellitus Patients With Non-Alcoholic Fatty Liver Disease [J].

Pokharel, Arbinda ;

Sudhamshu, K. C. ;

Thapa, Pukar ;

Karki, Niyanta ;

Shrestha, Rupesh ;

Jaishi, Bikash ;

Paudel, Mukesh S. .

CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (07)

[29] EMPAGLIFLOZIN: A NEW TREATMENT OPTION FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS [J].

Dailey, G. E. .

DRUGS OF TODAY, 2015, 51 (09) :519-535

[30] Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk [J].

Stalenhoef, A. F. H. ;

Davidson, M. H. ;

Robinson, J. G. ;

Burgess, T. ;

Duttlinger-Maddux, R. ;

Kallend, D. ;

Goldberg, A. C. ;

Bays, H. .

DIABETES OBESITY & METABOLISM, 2012, 14 (01) :30-39

← 1 2 3 4 5 →